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Abstract Microneedles (MNs) are a novel transdermal drug
delivery platform, rapidly progressing from a substantive ev-
idence base, towards commercialisation. As part of this tran-
sition, it is important to consider the future use of MNs by
older people in order to ensure optimal therapeutic outcomes
for this unique and increasing population group. This paper,
therefore, considers the use of MNs by those aged over
65 years, investigating insertion parameters in ageing skin,
alongside the feasibility and acceptability of the technology.
Hydrogel-forming MN arrays were applied to seven subjects
aged over 65 years, with breach of the stratum corneum con-
firmed using optical coherence tomography. Insertion depths
recorded in each case were similar to a comparative group,
aged 20–30 years. Skin recovery was, however, demonstrated
to occur at a slower rate in the older subjects, as measured
using transepidermal water loss. Qualitative methods, includ-
ing focus groups and semi-structured interviews, were
employed to collect the views and opinions of older people
and community pharmacists respectively. The overall consen-
sus was positive, with a number of benefits to MN-mediated
drug delivery identified, such as reduced dosing frequency,
improved adherence and an alternative delivery route where
oral or injectable medication was precluded. Concerns centred
on practical issues associated with age-related functional de-
cline, including, for example, reduced dexterity and skin
changes. The presentation of this work collectively provides
the first convincing report of the importance of further
translational research in this area to support future MN use
in older people, ensuring an age-appropriate delivery
platform.
Keywords Microneedles . Transdermal . Older people .
Optical coherence tomography . Transepidermal water loss
Introduction
It is evident that the global population is ageing, with the
number of people aged over 65 years increasing faster than
any other age group [1]. Care of this increasing population
presents a challenge, particularly given the typically high pro-
portion of associated morbidity and mortality [2]. Medication
is, therefore, a crucial intervention in the management of age-
ing, exemplified by the fact that more than half of those aged
65 years and over take at least three regular prescribed medi-
cines [3]. Considering new platforms for drug delivery,
microneedle (MN) technology is progressing towards relevant
clinical applications, offering a promising method for trans-
dermal drug delivery [4]. MN arrays consist of a plurality of
tiny projections on the micron scale, arranged on a supporting
base-plate and designed for application to the skin. The pri-
mary goal of such an approach is an increase in the number of
drug candidates for transdermal delivery, made possible by
circumvention of the rate-limiting barrier of the skin. MNs
cause temporary disruption of the stratum corneum, creating
microscopic aqueous pores through which drugs can diffuse to
the dermal microcirculation for subsequent systemic absorp-
tion. Transdermal drug delivery has a number of pertinent
advantages for the older adult, offering a viable alternative
to oral delivery, with the potential to provide sustained release
and minimise adverse effects [5]. Aligning these opportunities
alongside the typically high medication consumption of the
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older population, it follows that the specific use of MNs by
older people must be given due consideration to ensure the
greatest patient benefit.
The performance of an MN array, as an effective drug
delivery device, depends principally upon successful insertion
of the needles into the skin [6]. A tangible difference in the
skin occurs as a person ages, indeed, with these changes being
one of the greatest visual determinants of a person’s increasing
age. Increased dryness and decreased elasticity can be ob-
served, with a number of other changes noted, including epi-
dermal thinning and decreased dermal vascularity [7], in ad-
dition to a reduced rate of barrier repair [8]. It is, therefore,
clinically reasonable to assume that the skin response to MN
application in older adults may be different when compared to
those younger. A recent study used impedance spectroscopy
to examine skin recovery following MN treatment in older
people [9], reporting that micropore closure was slower in
older subjects when compared to a younger control group
[9]. As yet, however, there have been no detailed studies that
have investigated MN insertion and the associated parameters
in older people.
When developing a new technology for drug delivery, con-
sideration must be given to the patient who will be using it, as
well as other involved parties, for example, the healthcare
professionals who will be prescribing, dispensing and, in
some cases, administering the device. The acceptance of a
pharmaceutical product is closely linked to the success of
the innovation, both in commercial terms and also therapeuti-
cally. The latter may be predicted, as patient acceptance of a
device for drug delivery is typically interlinked with adher-
ence, a vital element in ensuring optimal treatment efficacy
and expected therapeutic outcomes [10]. By engagingwith the
patient early in the development process, potential issues can
be identified, which allows these factors to be addressed and
relevant adaptations to be made if necessary, ensuring that the
greatest benefit can be derived from the end product. To date,
studies investigating perceptions of MNs have yielded posi-
tive results, with members of the general public, children and
healthcare professionals all able to identify a number of ad-
vantages to MN use, whilst also highlighting where improve-
ments in MN patch design may be made [11–15]. There have
been no studies conducted, however, that have specifically
considered the views and opinions of older people, and those
involved in their care, on MNs for drug delivery, despite the
potential complexities of their treatment.
This study adopts a dual approach to assessing MN suit-
ability in older people, encompassing both the performance of
a MN array and the perspectives of end users and stake-
holders. Optical coherence tomography (OCT) was employed
as a technique to gain a full picture of MN insertion in older
adults when compared to those younger, specifically consid-
ering the depth and width of the created micropore, with
transepidermal water loss (TEWL) used simultaneously to
map the recovery of the skin following MN removal.
Qualitative methodologies were then also used to ascertain
the views and opinions of those aged over 65 years (focus
groups) and community pharmacists (semi-structured inter-
views), as a relevant healthcare professional, on the potential
use of MNs for drug delivery in the older population.
Materials and methods
Chemicals
Gantrez® S-97, a copolymer of methyl vinyl ether and maleic
acid, (PMVE/MA, molecular weight 1,500,000 Da) was a gift
from Ashland, Kidderminster, UK. Poly(ethylene glycol)
(PEG; molecular weight 10,000 Da) was purchased from
Sigma-Aldrich, Dorset UK. All other chemicals used were
of analytical reagent grade. Elastoplast® Invisible Protection
plasters were obtained fromBeiersdorf UKLtd., Birmingham,
UK.
Preparation of hydrogel-forming microneedle arrays
MN arrays were prepared from aqueous blends containing
20% w/w Gantrez® S-97 and 7.5% w/w PEG 10,000. The
blend (500 mg) was poured into laser-engineered silicone
micromoulds to form a MN array composed of 121
(11 × 11) needles, perpendicular to the base and of conical
shape, 600 μm high, on a 0.5 cm2 area, with a MN-free border
to give a final patch area of 1.0 cm2. The filled moulds were
centrifuged at 2205×g for 15 min and dried at room tempera-
ture for 48 h. MNs were then cross-linked (esterification reac-
tion) [16] by heating at 80 °C for 24 h, and the sidewalls
formed by the moulding process removed using a heated
blade. Finally, each MN array was affixed to an
Elastoplast® Invisible Protection plaster for application
purposes.
Participant recruitment
Ethical approval for the study was granted from the School of
Pharmacy Ethics committee at Queen’s University Belfast,
prior to commencement (014PMY2014, 018PMY2015).
Written informed consent was then obtained from subjects,
before enrolment in any part of the study. All participants in
the MN insertion experiment were either aged over 65 years,
forming the group under investigation, or aged 20–30 years,
acting as a control group. All had no pre-existing skin condi-
tions or allergy to plasters. Regarding participation in the fo-
cus groups, apart from an age of 65 years or older, there were
no further inclusion or exclusion criteria. Older participants
for both parts of the study were approached and invited to
participate through a local charity engaged in service
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provision for the over 65 years old age group. The participants
aged 20–30 years old were all employed at the School of
Pharmacy, Queen’s University Belfast, recruited by means of
an email circular. The only criterion for community pharma-
cist interviewees was that they had to be practicing in
Northern Ireland at the time of the interaction.
Insertion study procedure
The study was conducted at a controlled room temper-
ature of 20 °C within the School of Pharmacy, Queen’s
University Belfast. As the same environment was used
throughout, room humidity was not measured, which
was deemed to be consistent for each study participant.
Subjects rested within the room with their ventral fore-
arms uncovered for at least 15 min prior to the start of
the experiment to acclimatise. Two areas on the partic-
ipant’s ventral forearm were marked using a washable
pen and numbered 1 and 2. A baseline TEWL reading
was taken from the first marked location on the arm,
using a VapoMeter® (Delfin Technologies Ltd., Kuopio,
Finland), a closed-chamber, portable system which
operates via a sensitive humidity sensor. The sensor
monitors the increase of relative humidity inside the
chamber during the measurement, allowing the evapora-
tion rate value to be automatically calculated from the
relative increase. The TEWL values were obtained by
placing the meter on the relevant area on the forearm of
the participant, with the probe head vertical and perpen-
dicular to the skin, ensuring that the area of skin to be
analysed was sealed by the adapter. Skin contact was
maintained for approximately 10 s before generation of
an evaporation rate value. The researcher then applied
an MN patch to this area, using thumb pressure, in the
direction of the skin, held for 30 s and timed using a
stopwatch. Once inserted, the MN array was visualised
in situ using the handheld probe of the VivoSight®
topical OCT system (Michelson Diagnostics Ltd., Kent,
UK). The swept-source Fourier domain OCT system has
a laser centre wavelength of 1305 ± 15 nm, facilitating
real-time high-resolution imaging of the upper skin
layers (depth ∼ 2 mm, <7.5 μm lateral and <10 μm
vertical resolution). The resultant 2D images from
OCT scans were analysed using the imaging software
ImageJ® (National Institute of Health, MD, USA). The
scale of the image files obtained was 1.0 pixel = 4.2 μm,
thus allowing accurate measurements of the depth of
MN penetration and the width of pore created in the
skin. For each subject, OCT data were presented as
mean (±S.D.) of 12 replicate measurements of individual
MN insertion depth and the diameter of the corresponding
micropore, where the measured MNs were selected at random
from the 121 penetrating needles in each array. The MN patch
was removed from the skin following OCT use, and a TEWL
measurement of the area was taken immediately. This area of
skin was then left untouched for 30 min before a final TEWL
measurement was recorded.
The secondMN application was performed on the location
labelled number 2 on the ventral forearm; this time applied by
the volunteer themselves. As before, a baseline TEWL mea-
surement was taken from this location prior to application.
The subject was then asked to apply the MN patch by repli-
cating what the researcher had done previously. In this way, no
formal counselling was provided and the participant had to
rely on experience from the former application. As described
previously, OCT scans were taken of the inserted MN array,
prior to its removal. TEWL measurements were taken imme-
diately post removal and after 30 min.
Questionnaire
A short, structured questionnaire, consisting of eight fixed
questions, was devised to collect demographic data from the
insertion study participants, as well as their views and opin-
ions of the application process they had just experienced, with
their answers based on a Likert scale. Questionnaires were
designed in consultation with MN and pharmacy practice re-
searchers and piloted with staff and post-graduate students in
the School of Pharmacy to ensure understanding of questions
and ease of response.
Focus groups
Focus groups were employed to assess the perspectives of
older people on the use of MN technology. Such a methodol-
ogy has been deemed particularly useful when knowledge on
the issue in question is lacking, which, given the novelty of
this topic, was the context for this study [17]. The group in-
teraction promotes discussion, thus leading to a greater appre-
ciation of older people’s views than one-to-one questioning
[18]. A topic guide for focus group discussion was developed
according to previous studies investigating MNs using quali-
tative methodologies [11–13, 15], and then piloted to refine
content and ensure validity. Each focus group began with
simple introductory questions relating to medication use and
common issues encountered, before progressing to the con-
cept of MNs and discussion points on the use of such a tech-
nology by older people, as summarised in Fig. 1a. To facilitate
discussion, an introduction toMNs was provided using a short
presentation, explaining what they were and their potential
role in drug delivery. Sample MN arrays, produced for exper-
imental purposes (Fig. 1b), were distributed for inspection, as
well as an oversized prototype MN array contained within a
sealed Perspex box (Fig. 1c). Each focus group ended with a
short summary of the discussion and the opportunity to ask
any further questions.
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Community pharmacist interviews
Semi-structured interviews were used to investigate the
views and opinions of community pharmacists on the
use of MNs by older people. It was anticipated that phar-
macists would have knowledge of emerging drug delivery
technologies, in addition to experience of medication
management in older adults; hence, interviews were
viewed as suitable to focus on the topic and achieve an
appropriate level of detail. The interviews were designed
to follow a similar semi-structured topic guide to that used
for focus groups, developed and piloted as previously de-
scribed. As an introduction, the interview began by estab-
lishing if the pharmacist had any prior knowledge of
MNs. Irrespective of the answer, an explanation of MNs
was then provided, using a short presentation to explain
what MNs were and how they worked, with an appropri-
ate level of detail for a healthcare professional. The main
interview questions then related to the use of MN tech-
nology in older people and the challenges and opportuni-
ties relating to the introduction of such a technology into
community pharmacy practice, as summarised in Fig. 1a.
Qualitative data handling and analysis
All focus groups and interviews were audio-recorded using
a digital voice recorder (Olympus WS-321M, Olympus
Corporation, Tokyo, Japan). Recruitment and data collec-
tion ceased when data saturation was deemed to have oc-
curred, noted as the appearance of no new themes emerg-
ing with subsequent focus groups or interviews. Audio
recordings were transcribed verbatim, all identifiers re-
moved and codes assigned to participants (to ensure ano-
nymity) before being imported to NVivo® (QSR
International Pty Ltd., Doncaster, Australia) for thematic
analysis. Broad themes were identified and analysed by
constant comparison between and within transcripts. By
including both community pharmacists and older people,
the research question was explored from various perspec-
tives, a concept known as data triangulation, an approach
credited with improving the validity of qualitative study
findings [19]. Common themes were then grouped together
into subthemes, and following further refinement, core
themes, identified to accurately represent the entire data
set. Consensus on the emergent themes was reached by
discussion among all three researchers (HQ, CH, RD).
Statistical analysis
Where appropriate, data was analysed using a t test, Mann-
Whitney U test or a one-way analysis of variance (ANOVA),
with post-hoc comparison performed using Tukey’s HSD test.
In all cases, p < 0.05 denoted significance.
Results
Insertion study subjects
A total of 15 people were recruited to the insertion study.
Seven participants were aged over 65 years (four male), with
a maximum age of 82 years, and eight were aged between 20
and 30 years (four male). MN application was well tolerated
by all subjects, with no local reactions or adverse effects ob-
served over the course of the study.
Optical coherence tomography
The mean insertion depths and pore widths upon MN
application were measured as shown in Fig. 2, and the
Fig. 1 Topic guide for focus
groups and semi-structured inter-
views (a); 1 cm2 polymeric MN
array (b); and oversizedMN array
enclosed within a Perspex box (c),
both used for demonstration
purposes
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resultant findings are presented in Table 1. Comparing
researcher and self-application within each age group, in
the 20–30 year olds, there was no difference in the
resulting insertion depths (p = 0.18), whereas in the
≥65 year olds, researcher application resulted in signifi-
cantly lower insertion depths than when self-applied
(p = 0.016). Indeed, the insertion depths resulting from
researcher application of MN patches in the ≥65 years
age group were found to be significantly lower than both
researcher and self-application in the 20–30 year olds
(p = 0.0014). However, there was shown to be no differ-
ence between the MN application in the 20–30 year olds
and the self-application in the ≥65 year olds. There was
no significant difference in the pore widths created by
MN insertion in any of the application types or age
groups (p = 0.30).
Transepidermal water loss
The initial baseline TEWL differed significantly between the
two age groups (p < 0.0001), with a mean value of 4.94 g/m2 h
measured in the ≥65 year olds, compared to 9.31 g/m2 h in the
20–30 year olds. Upon MN application and subsequent re-
moval, there was a significant increase in TEWL in both age
groups, which decreased after 30 min but remained signifi-
cantly higher than baseline (Fig. 3). In the 20–30 year olds, the
percentage difference from baseline after 30 min was only
17.59%whereas in the older age group, the percentage change
remained high, at 71.61% greater than the original value.
Post-application questionnaire
All participants were positive about MN technology, with
100% of participants willing to use them again in the future.
Similarly, all were satisfied or very satisfied with the ease and
comfort of MN application and confident or very confident in
applying the MN patch to themselves.
Focus group and interview participants
A total of five focus groups were conducted, with 7–10 people
in each, providing an overall total of 41 participants, ranging
in age from 65 to 86 years. Regarding interviews, a total of 12
community pharmacists took part, with the mean number of
years post registration as a pharmacist being 12.2. Focus
groups lasted, on average, 67 min, whilst pharmacist inter-
views lasted approximately 22 min. All participants were
assigned a unique identifier code such as ‘FG1_M_67’, which
indicated that this was a member of focus group 1, male, aged
67 years. If there was more than one person of the same age
and sex in the same group, A, B and C were used to further
differentiate the participant. For the interviews, codes such as
‘CP_3’ were employed, which referred to community phar-
macist number 3, numbered according to the sequence of the
interviews conducted.
Fig. 2 Representative OCT image of a MN, displaying the measurement
of the insertion depth (a) and pore width (b) upon application
Table 1 Insertion depths and pore widths measured from polymeric
MN application, by the researcher and by the subject themselves
(mean ± S.D., n ≥ 7)
Age (years) Applicator Insertion depth (μm) Pore width (μm)
20–30 Researcher 356 ± 21.6 279 ± 24.0
Self 371 ± 16.1 283 ± 13.8
65 Researcher 321 ± 14. 8 292 ± 11.7
Self 347 ± 30.3 294 ± 19.0 Fig. 3 Change in TEWL from baseline following MN application and
removal up to 30 min (mean ± S.D., n ≥ 7)
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Main themes
Following detailed thematic analysis, five themes were iden-
tified, as illustrated in Fig. 4, three of which were common
across the focus groups and interviews: device features, clin-
ical applications and patient-related factors. One theme result-
ed from focus group discussions only, namely, current expe-
riences of medication, and one further theme from the inter-
views only, that is, the pharmacist’s role.
Device features
The features of a MN product were extensively discussed as
older people contemplated their ability to handle such a patch.
The size and colour were particular areas of focus, with the
acknowledgment that both would have a large impact on an
older person’s handling of a MN patch. The packaging of the
device was also considered, as older people explained the
frequent difficulties encountered in removing medication
from its packet. Participants were positive about the possible
inclusion of a colour change upon application of pressure and
insertion, remarking that Bit would give older people confi-
dence, knowing that they were taking their medication right^
(CP_9).
Clinical applications
A number of drugs were suggested for delivery via MNs,
some chosen according to the circumstances of the patient
and others according to the properties of the drug. For exam-
ple, donepezil for treatment of dementia in Alzheimer’s dis-
ease was named by a number of participants, with the rationale
that patients prescribed this drug often demonstrated
swallowing and/or adherence issues. The other type of drug
most frequently suggested was that which provoked gastroin-
testinal adverse effects, e.g. non-steroidal anti-inflammatory
drugs (NSAIDs), as, if using a MN patch, Byou wouldn’t have
the side effects of it upsetting your stomach or your bowel
because it’s not going that way^ (FG5_F_85). The community
pharmacist interviewees expressed reluctance towards the in-
corporation of drugs that would require regular monitoring or
frequent dosage alterations, with a preference noted for long-
term medication on which the patient was stable. Participants
also recognised the opportunity for sustained delivery of drugs
using MNs, identifying this as a further positive feature which
may reduce adverse effects and improve adherence, Binstead
of having to take a statin [cholesterol-lowering drug] every
day, you’ll be able to put a patch on and it will last for a week^
(FG1_M_70A).
Patient-related factors
The utility of MNs as an alternative delivery route where
patient circumstances may preclude the use of other common
routes for medication administration was highlighted as being
particularly beneficial in the older population, and indeed, this
is where a number of participants saw the principal advantage
of MN use in this group. Difficulty in administration of injec-
tions, poor or no swallow, alongside refusal to take oral prep-
arations in cognitively impaired patients were the main prob-
lems cited, of which some of the participants had personal or
professional experience.
The majority of participants believed older people would
be able to apply a MN patch effectively, comparing it to ap-
plication of a sticking plaster or a conventional transdermal
patch. Loss of dexterity and vision were cited as the most
likely barriers to the practical use of a MN device, although
if designed appropriately, these were not believed to be limit-
ing factors. Another issue discussed was the changes observed
in the skin upon ageing, with apprehension expressed as to
whether these differences could have an impact on effective
MN usage. Similarly, concern was expressed whether older
people would be more susceptible to damage or irritation, due
to changes in hydration and the increased fragility of ageing
skin.
Considering the acceptability of a MN product, older peo-
ple rejected the stereotype often associated with their age
group, stating that, Bit’s not really an assumption to make, in
that because somebody is older, that they won’t be open to a
new idea^ (FG3_F_74). Although it was acknowledged that
there was likely to be some reluctance about a change from an
accepted conventional delivery form, such as a tablet, to a MN
patch, appropriate education and professional advice were de-
scribed as sufficient to overcome any concerns.
Current experiences of medication
Older people reported a complex situation when asked about
their current experiences of taking medication. The combina-
tion of an uncertain relationship with the prescriber, limited
information regarding their medication and practical issues
regarding medicine management and administration frequent-
ly led to non-ideal medication use. There was little experience
of using transdermal patches by the older people involved,
although participants were aware there was only a limited
Fig. 4 Schematic illustration of themes identified from focus groupswith
older people and semi-structured interviews with community pharmacists
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number of transdermal patches currently available for drug
delivery.
Pharmacist’s role
The pharmacists identified their primary role to be in counsel-
ling patients on MN use following supply, deemed to be par-
ticularly important, considering the novelty of MNs.
Pharmacists expressed confidence regarding counselling on
an MN patch, suggesting a number of supporting materials
to assist with the counselling process, including a placebo
patch, training video and diagrams, in addition to the patient
information leaflet. The main barrier to implementation of the
counselling strategies proposed was having the time that
would be required to ensure understanding, rather than the
age of the patient per se.
Discussion
As a novel drug delivery technology, the future use of MNs
across the entire population must be carefully considered to
ensure the greatest impact in terms of both patient and com-
mercial outcomes. This is of particular relevance for the older
population, a heterogeneous group who may demonstrate dif-
ferent needs to younger adults, in terms of their pharmaceuti-
cal care [20]. The present study was, therefore, conducted in
order to assess the applicability of MNs for drug delivery
specifically in those aged over 65 years.
In the first instance, the practical application of MNs to
ageing skin was considered, focusing on insertion of the
needles and the subsequent recovery of the skin following
MN removal. MN arrays of a previously optimised and vali-
dated design, in terms of material, geometry and needle di-
mensions, were employed [21], with the variable being the
age of the subject. Further to this, in order to investigate the
ability of older people to self-apply the MN arrays, one appli-
cation was performed by the subject to him or herself, in
addition to the application carried out by the researcher.
Overall, from the two applications, the mean insertion depths
obtained ranged from 60.6% of the MN height penetrating in
the 20–30 year olds to 55.7% in those aged over 65 years,
which is in line with recent studies investigating the insertion
of this design of polymeric MNs [22, 23]. This observation
demonstrates the relative similarity of MN insertion in the two
age groups. A significant difference was, however, noted be-
tween the insertion depths of the MNs in the arrays applied by
the researcher to the older subjects, in comparison to both
applications in the younger group. When self-applied by the
older subjects, this difference was not observed, with the mean
insertion depth comparable to the 20–30 year olds. This im-
plies that the lower insertion depth observed initially may be
due, at least in part, to the application process, as conducted by
the researcher, who may have exercised excessive caution in
terms of the pressure applied to the array due to the age of the
subject. The other theory for the lower insertion depth, as
previously hypothesised in the literature, is that a greater force
may be required for MN insertion in ageing skin [24].
Nevertheless, in all cases, the MNs efficiently traversed the
stratum corneum and, with a maximum range between inser-
tion depths of only 49.4 μm, any consequences for drug de-
livery are likely to be arbitrary [25, 26]. Indeed, with
hydrogel-forming MNs, once the array begins to absorb inter-
stitial fluid from the skin and swell, little difference in pene-
tration depth is observed from that point on, minimising any
effect from initial differences [27]. The other parameter mea-
sured upon MN insertion was the width of the micropore
formed in the skin. Typically, due to the conical shape of the
needles, the greater the insertion depth, the greater the width
of the pore it creates in the skin. Although the mean insertion
depth for those aged over 65 years was lower than the 20–
30 years old, the corresponding mean pore widths were
higher, albeit not significantly. One possible theory for this
disparity is due to the decreased elasticity of ageing skin,
which may be contributing to a decreased enveloping of the
needles when they puncture the skin surface, hence, creating a
larger pore diameter around each MN [25]. For MNs which
remain in place for the duration of drug delivery, such as the
hydrogel-forming platform used in this study, the size of the
pore is of little consequence for drug diffusion, as the
permeant moves through the MN matrix itself; however, such
a finding may have implications for the recovery of the skin.
It is naturally of great importance that MNs do not
cause lasting damage to the skin and the integrity of the
barrier can be restored upon MN removal. TEWL was,
therefore, used as a means of measuring skin recovery in
the present study. The baseline TEWL recorded was sig-
nificantly lower in the older sample group than in the
younger age group, which, despite appearing counter-in-
tuitive, is in line with previous findings of TEWL in the
older population [28]. The general pattern of the changes
in TEWL following MN application and removal was as
expected, with a significant increase noted immediately
upon MN removal and a subsequent decrease after
30 min [29]. Importantly, the trend observed was similar
between the two age groups. There was a greater percent-
age increase in TEWL immediately following MN remov-
al in the older group (143.1% compared to 59.47%),
which remained notably above baseline after 30 min.
This may indicate that ageing skin recovers at a slower
rate than that of younger counterparts, which could be
linked to the decreased elasticity and declined rate of bar-
rier repair, common in ageing skin [30]. Further measure-
ment of TEWL beyond 30 min would be required to con-
firm this theory, however. Importantly though, there was a
28.0% decrease in the TEWL of the over 65 year olds
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over the 30 min period following MN removal, demon-
strating that the skin is capable of recovering within a
reasonable time frame.
The favourable attitudes towards MNs revealed by the
qualitative investigations echo the results of prior studies on
the acceptability of a MN platform for drug delivery [11, 15,
31]. Older people highlighted the perceived benefits of MNs
as an alternative route for drug delivery, in contrast to the
issues often experienced with both oral preparations and in-
jectables. For example, swallowing difficulties are known to
be common in the older population, associated with increasing
age and the presence of certain conditions such as Parkinson’s
disease and dementia [32]. Delivery via injection may also be
more problematic in older people, due to limited venous ac-
cess as a result of low body weight and decreased muscle
mass, often associated with frailty [33]. Transdermal therapy
was indicated as being extremely useful in these circum-
stances, permitting medication administration with ease and
maximising patient convenience. Indeed, the participants in
the present study noted a potential improvement in adherence
with MN use, an advantage not previously identified. There
are existing reports of improved adherence in the older popu-
lation due to transdermal drug delivery, with specific exam-
ples relating to the treatment of Alzheimer’s disease [34, 35].
Such improvements in adherence may be due in part to the
ability of a caregiver to effectively facilitate application of a
transdermal patch, in comparison to the difficulties faced in
administration of an oral preparation to a patient or family
member, who may be exhibiting severely reduced mental
and or physical capacity. The use of MNs in this context
could, therefore, offer great patient benefit.
A notable advantage of a MN system is the option of self-
administration, particularly when compared to hypodermic
injection, which typically requires a healthcare professional
for administration. It has been previously demonstrated that
hydrogel-forming MNs can be effectively self-inserted by a
group of undergraduate pharmacy students, with the assis-
tance of pharmacist counselling and a patient information leaf-
let [23]. Further evidence would be desirable to extend this
principle to older people, who often exhibit a decline in func-
tional capacity, including decrements in cognitive, visual or
motoric capabilities [36]. Considering practical handling, the
decrease in motor function may manifest as difficulties in
manipulation and handling of medication, due to slower, less
coordinated and less controlled performances in tasks such as
this which require a degree of hand dexterity [37].
Encouragingly, however, all participants in the present study
were able to apply a MN patch to themselves, and stated that
they were confident or very confident in doing so. The qual-
itative study also revealed similar confidence with respect to
potential application of a MN patch, providing that size and
colour were considered. Distinct from the MN array but still
vital for usability purposes is the packaging of the final
product. This was highlighted in both aspects of the study,
with the topic extensively discussed in the qualitative interac-
tions and assistance required in some cases during the inser-
tion experiments to remove the backing from the adhesive
plaster before MN application. The issues older people have
in opening and handling medication are well known, although
they are still not always recognised in product design [38].
In order to facilitate the safe and effective use of a MN
product by community-dwelling older people, engagement
by the pharmacy profession would be required, due to their
involvement in patient counselling, particularly critical with a
new drug or device [39]. The community pharmacists
interviewed here clearly identified their own role in the
counselling and education of the patient on the use of MNs,
expressing their belief that, following their intervention, older
people would be able to use MNs safely and effectively. To
ensure optimal therapeutic outcomes, there is evidence to sug-
gest that patients’ capacity to manage new medication deliv-
ery systems should be tested with simulated devices prior to
home use [40, 41], reinforcing the need for a placebo MN
patch for training purposes, as recommended by the pharma-
cists here.
Some unique questions relating to MN use were raised,
specific to this age group, reiterating the value of stakeholder
engagement early in the development process. Pharmacists
and older people expressed concern as to whether MNs could
be rendered ineffective, due to the age-related changes ob-
served in skin or whether adaptations would need to be made
to the MN dimensions for use in older people. Comparing it to
conventional transdermal drug delivery using patches, there
are currently no known differences observed in practice be-
tween passive absorption in young and older (over 65 years)
individuals [5]. As an example, when treating those aged over
75 years compared to those aged 50–60 years, no dosage
alteration of buprenorphine patches was necessary [42]. The
use ofMNs themselves in older people, however, as this study
has highl ighted, warrants fur ther inves t iga t ion.
Encouragingly, to date, no unusual skin responses to MN in-
sertion have been recorded in those over a certain age [9],
despite the overt changes in skin anatomy.
There are a number of factors that should be noted, when
interpreting the results and considering the further develop-
ment of this work. Firstly, it must be highlighted that this study
considered a small number of subjects, so any differences
observed in MN insertion and skin recovery would need to
be validated in larger populations. A longer follow-up period
after MN application, alongside a longer insertion time where
the MNs remained in place for up to 24 h, would also warrant
further investigation. Considering the qualitative results, given
their nature, it must be acknowledged that the data cannot be
broadly generalised, although the findings may be transfer-
able. Further to this, an explanation of MNs was given at the
beginning of every interaction due to the novelty of the topic
Drug Deliv. and Transl. Res.
and, although strictly factual in nature, this information may
have affected the responses provided.
Conclusion
In the present study, MN insertion in ageing skin and the
subsequent recovery of the skin were evaluated, highlighting
successful breach of the stratum corneum upon application in
older subjects and a degree of skin recovery within 30 min.
The views and opinions of older people and community phar-
macists regarding MN use were collected, providing key in-
sights into the perspectives of those who would be involved in
the end use of the technology. The likely acceptability of the
technology and the engagement of community pharmacists
were encouraging findings from these qualitative investiga-
tions. The presentation of this evidence collectively provides
a strong basis for further research in this area and future clin-
ical studies in this key target population.
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